Today, the EVPChief Commercial Officer of Vertex Pharmaceuticals (VRTX), Stuart Arbuckle, bought shares of VRTX for $795.7K.
This recent transaction increases Stuart Arbuckle’s holding in the company by 18.43% to a total of $6.83 million. Following Stuart Arbuckle’s last VRTX Buy transaction on November 08, 2018, the stock climbed by 6.8%.
See today’s analyst top recommended stocks >>
Based on Vertex Pharmaceuticals’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $783 million and quarterly net profit of $129 million. In comparison, last year the company earned revenue of $652 million and had a net profit of $101 million. VRTX’s market cap is $47.8B and the company has a P/E ratio of 74.81. Currently, Vertex Pharmaceuticals has an average volume of 1.89M.
14 different firms, including Barclays and BMO Capital, currently also have a Buy rating on the stock. Based on 16 analyst ratings, the analyst consensus is Strong Buy with an average price target of $210.00, reflecting a 15.1% upside.
The insider sentiment on Vertex Pharmaceuticals has been positive according to 112 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis; infectious diseases, including viral infections, such as influenza, and bacterial infections; autoimmune diseases, such as rheumatoid arthritis; cancer, inflammatory bowel disease; and neurological disorders, including pain, Huntington’s disease and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
